Last updated: December 3, 2024
Sponsor: University of Reading
Overall Status: Active - Recruiting
Phase
N/A
Condition
Autism
Autism Spectrum Disorder (Asd)
Treatment
Placebo
Pyridoxal 5'-Phosphate (100 mg)
Clinical Study ID
NCT06234501
UREC23/27
Ages 18-60 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Between the ages of 18 to 60
With a diagnosis of autism
Exclusion
Exclusion Criteria:
Taking any supplement that contains more than 2mg of Vitamin B6 or taking GABAagonist drugs
Have a medical history of peripheral neuropathy
lactose intolerance (placebo tablet is lactose based)
Study Design
Total Participants: 40
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
November 08, 2024
Estimated Completion Date:
October 31, 2025
Study Description
Connect with a study center
University of Reading
Reading, RG6 6AL
United KingdomActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.